- Home
- OCGN vs SLN Comparison
OCGN vs SLN Comparison
Compare OCGN & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCGN
- SLN
- Stock Information
- Founded
- OCGN 2013
- SLN 1994
- Country
- OCGN United States
- SLN United Kingdom
- Employees
- OCGN N/A
- SLN N/A
- Industry
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- OCGN Health Care
- SLN Health Care
- Exchange
- OCGN Nasdaq
- SLN Nasdaq
- Market Cap
- OCGN 278.3M
- SLN 281.0M
- IPO Year
- OCGN N/A
- SLN N/A
- Fundamental
- Price
- OCGN $1.03
- SLN $5.92
- Analyst Decision
- OCGN Strong Buy
- SLN Buy
- Analyst Count
- OCGN 3
- SLN 5
- Target Price
- OCGN $6.00
- SLN $32.60
- AVG Volume (30 Days)
- OCGN 8.5M
- SLN 120.4K
- Earning Date
- OCGN 08-07-2025
- SLN 08-14-2025
- Dividend Yield
- OCGN N/A
- SLN N/A
- EPS Growth
- OCGN N/A
- SLN N/A
- EPS
- OCGN N/A
- SLN N/A
- Revenue
- OCGN $4,522,000.00
- SLN $27,701,000.00
- Revenue This Year
- OCGN N/A
- SLN N/A
- Revenue Next Year
- OCGN N/A
- SLN N/A
- P/E Ratio
- OCGN N/A
- SLN N/A
- Revenue Growth
- OCGN N/A
- SLN N/A
- 52 Week Low
- OCGN $0.52
- SLN $1.97
- 52 Week High
- OCGN $1.98
- SLN $22.47
- Technical
- Relative Strength Index (RSI)
- OCGN 55.00
- SLN 58.20
- Support Level
- OCGN $0.95
- SLN $5.06
- Resistance Level
- OCGN $1.15
- SLN $6.25
- Average True Range (ATR)
- OCGN 0.11
- SLN 0.48
- MACD
- OCGN -0.02
- SLN -0.03
- Stochastic Oscillator
- OCGN 22.62
- SLN 63.20
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.